SG11201809543QA - Treatment of complement-mediated disorders - Google Patents
Treatment of complement-mediated disordersInfo
- Publication number
- SG11201809543QA SG11201809543QA SG11201809543QA SG11201809543QA SG11201809543QA SG 11201809543Q A SG11201809543Q A SG 11201809543QA SG 11201809543Q A SG11201809543Q A SG 11201809543QA SG 11201809543Q A SG11201809543Q A SG 11201809543QA SG 11201809543Q A SG11201809543Q A SG 11201809543QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- complement
- treatment
- factor
- westmead
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1608046.7A GB201608046D0 (en) | 2016-05-09 | 2016-05-09 | Treatment of complement-mediated disorders |
PCT/GB2017/051233 WO2017194912A1 (fr) | 2016-05-09 | 2017-05-03 | Traitement de troubles médiés par le complément |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809543QA true SG11201809543QA (en) | 2018-11-29 |
Family
ID=56297354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809543QA SG11201809543QA (en) | 2016-05-09 | 2017-05-03 | Treatment of complement-mediated disorders |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200147240A1 (fr) |
EP (1) | EP3454910A1 (fr) |
JP (1) | JP7178905B2 (fr) |
KR (2) | KR20230047420A (fr) |
CN (1) | CN109328076B (fr) |
AU (2) | AU2017264750B2 (fr) |
CA (1) | CA3022500A1 (fr) |
GB (1) | GB201608046D0 (fr) |
IL (1) | IL262852A (fr) |
MX (1) | MX2018013665A (fr) |
RU (1) | RU2768982C2 (fr) |
SG (1) | SG11201809543QA (fr) |
WO (1) | WO2017194912A1 (fr) |
ZA (1) | ZA201807218B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
WO2020086735A1 (fr) * | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions et méthodes de traitement de la dégénérescence maculaire liée à l'âge et d'autres maladies |
GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
GB201821089D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
JP2022541275A (ja) * | 2019-07-17 | 2022-09-22 | ジェミニ・セラピューティクス・サブ・インコーポレイテッド | H因子増強性抗体及びその使用 |
MX2022004939A (es) * | 2019-10-23 | 2022-08-10 | Gemini Therapeutics Sub Inc | Metodos para tratar pacientes que tienen mutaciones de cfh con proteinas de cfh recombinantes. |
GB202009741D0 (en) * | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
EP4214242A1 (fr) * | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Anticorps vectorisés pour thérapie antivirale |
GB202018320D0 (en) * | 2020-11-20 | 2021-01-06 | Univ Newcastle | Methods of producing recombinant complement proteins |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11514853A (ja) * | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
WO1998010088A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
NZ532635A (en) * | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
PT1625210E (pt) | 2003-05-21 | 2011-03-15 | Genzyme Corp | Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios |
WO2006036502A2 (fr) | 2004-09-22 | 2006-04-06 | St. Jude Children's Research Hospital | Expression amelioree du facteur ix dans les vecteurs de therapie genique |
CN101809034B (zh) * | 2007-06-07 | 2015-07-08 | 健泰科生物技术公司 | C3b抗体及用于预防和治疗补体相关病症的方法 |
EP4154903A1 (fr) * | 2008-04-22 | 2023-03-29 | Vib Vzw | Éléments régulateurs d'acides nucléiques spécifiques au foie et procédés et leur utilisation |
GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
HUE028341T2 (en) | 2009-06-16 | 2016-12-28 | Genzyme Corp | Improved methods for purifying recombinant AAV vectors |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
EP3795581A3 (fr) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | Nouvelles protéines de capside avv pour le transfert d'acides nucléiques |
CN114395559A (zh) * | 2014-04-25 | 2022-04-26 | 吉尼松公司 | 高胆红素血症的治疗 |
HUE054768T2 (hu) | 2014-05-02 | 2021-09-28 | Genzyme Corp | AAV vektorok retina és CNS génterápiára |
CA2959376A1 (fr) * | 2014-08-28 | 2016-03-03 | Tufts University | Compositions, procedes et kits pour le traitement des troubles lies au complement |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
-
2016
- 2016-05-09 GB GBGB1608046.7A patent/GB201608046D0/en not_active Ceased
-
2017
- 2017-05-03 MX MX2018013665A patent/MX2018013665A/es unknown
- 2017-05-03 CN CN201780038436.1A patent/CN109328076B/zh active Active
- 2017-05-03 US US16/099,880 patent/US20200147240A1/en active Pending
- 2017-05-03 JP JP2018559206A patent/JP7178905B2/ja active Active
- 2017-05-03 CA CA3022500A patent/CA3022500A1/fr active Pending
- 2017-05-03 RU RU2018143411A patent/RU2768982C2/ru active
- 2017-05-03 EP EP17723742.7A patent/EP3454910A1/fr active Pending
- 2017-05-03 KR KR1020237006954A patent/KR20230047420A/ko not_active Application Discontinuation
- 2017-05-03 WO PCT/GB2017/051233 patent/WO2017194912A1/fr unknown
- 2017-05-03 SG SG11201809543QA patent/SG11201809543QA/en unknown
- 2017-05-03 KR KR1020187034843A patent/KR20190019065A/ko not_active IP Right Cessation
- 2017-05-03 AU AU2017264750A patent/AU2017264750B2/en active Active
-
2018
- 2018-10-29 ZA ZA2018/07218A patent/ZA201807218B/en unknown
- 2018-11-07 IL IL262852A patent/IL262852A/en unknown
-
2023
- 2023-04-05 AU AU2023202099A patent/AU2023202099A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017264750A1 (en) | 2018-12-13 |
RU2018143411A (ru) | 2020-06-10 |
RU2018143411A3 (fr) | 2020-09-30 |
RU2768982C2 (ru) | 2022-03-28 |
AU2017264750B2 (en) | 2023-01-05 |
CN109328076A (zh) | 2019-02-12 |
US20200147240A1 (en) | 2020-05-14 |
GB201608046D0 (en) | 2016-06-22 |
IL262852A (en) | 2018-12-31 |
EP3454910A1 (fr) | 2019-03-20 |
JP7178905B2 (ja) | 2022-11-28 |
CN109328076B (zh) | 2024-03-01 |
WO2017194912A1 (fr) | 2017-11-16 |
AU2023202099A1 (en) | 2023-07-06 |
KR20190019065A (ko) | 2019-02-26 |
JP2019519494A (ja) | 2019-07-11 |
ZA201807218B (en) | 2023-12-20 |
CA3022500A1 (fr) | 2017-11-16 |
KR20230047420A (ko) | 2023-04-07 |
MX2018013665A (es) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809543QA (en) | Treatment of complement-mediated disorders | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201808422QA (en) | Gene therapy for treating hemophilia a | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |